An Open Label Dose Escalation Study Of E7080

NCT00121719 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor or Lymphoma

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Inc.